BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 33186344)

  • 21. No prognostic value of IDH1 mutations in a series of 100 WHO grade II astrocytomas.
    Ahmadi R; Stockhammer F; Becker N; Hohlen K; Misch M; Christians A; Dictus C; Herold-Mende C; Capper D; Unterberg A; von Deimling A; Wick W; Hartmann C
    J Neurooncol; 2012 Aug; 109(1):15-22. PubMed ID: 22528790
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Malignant astrocytomas of elderly patients lack favorable molecular markers: an analysis of the NOA-08 study collective.
    Wiestler B; Claus R; Hartlieb SA; Schliesser MG; Weiss EK; Hielscher T; Platten M; Dittmann LM; Meisner C; Felsberg J; Happold C; Simon M; Nikkhah G; Papsdorf K; Steinbach JP; Sabel M; Grimm C; Weichenhan D; Tews B; Reifenberger G; Capper D; Müller W; Plass C; Weller M; Wick W;
    Neuro Oncol; 2013 Aug; 15(8):1017-26. PubMed ID: 23595628
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular profile of tumors with oligodendroglial morphology: Clinical relevance.
    Geevar T; Pai R; Chacko G; Malepathi K; Patel B; John J; Chacko AG; Balakrishnan R; John S
    Neurol India; 2018; 66(6):1726-1731. PubMed ID: 30504574
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative study of IDH1 mutations in gliomas by high resolution melting analysis, immunohistochemistry and direct DNA sequencing.
    Li J; Zhang H; Wang L; Yang C; Lai H; Zhang W; Chen X; Wang J
    Mol Med Rep; 2015 Sep; 12(3):4376-4381. PubMed ID: 26130305
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Polysialic acid is associated with better prognosis and IDH1-mutation in diffusely infiltrating astrocytomas.
    Mäkelä K; Nordfors K; Finne J; Jokilammi A; Paavonen T; Haapasalo H; Korja M; Haapasalo J
    BMC Cancer; 2014 Aug; 14():623. PubMed ID: 25164322
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Survival of diffuse astrocytic glioma, IDH1/2 wildtype, with molecular features of glioblastoma, WHO grade IV: a confirmation of the cIMPACT-NOW criteria.
    Tesileanu CMS; Dirven L; Wijnenga MMJ; Koekkoek JAF; Vincent AJPE; Dubbink HJ; Atmodimedjo PN; Kros JM; van Duinen SG; Smits M; Taphoorn MJB; French PJ; van den Bent MJ
    Neuro Oncol; 2020 Apr; 22(4):515-523. PubMed ID: 31637414
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A new sensitive PCR assay for one-step detection of 12 IDH1/2 mutations in glioma.
    Catteau A; Girardi H; Monville F; Poggionovo C; Carpentier S; Frayssinet V; Voss J; Jenkins R; Boisselier B; Mokhtari K; Sanson M; Peyro-Saint-Paul H; Giannini C
    Acta Neuropathol Commun; 2014 Jun; 2():58. PubMed ID: 24889502
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anaplastic astrocytoma with piloid features, a novel molecular class of IDH wildtype glioma with recurrent MAPK pathway, CDKN2A/B and ATRX alterations.
    Reinhardt A; Stichel D; Schrimpf D; Sahm F; Korshunov A; Reuss DE; Koelsche C; Huang K; Wefers AK; Hovestadt V; Sill M; Gramatzki D; Felsberg J; Reifenberger G; Koch A; Thomale UW; Becker A; Hans VH; Prinz M; Staszewski O; Acker T; Dohmen H; Hartmann C; Mueller W; Tuffaha MSA; Paulus W; Heß K; Brokinkel B; Schittenhelm J; Monoranu CM; Kessler AF; Loehr M; Buslei R; Deckert M; Mawrin C; Kohlhof P; Hewer E; Olar A; Rodriguez FJ; Giannini C; NageswaraRao AA; Tabori U; Nunes NM; Weller M; Pohl U; Jaunmuktane Z; Brandner S; Unterberg A; Hänggi D; Platten M; Pfister SM; Wick W; Herold-Mende C; Jones DTW; von Deimling A; Capper D
    Acta Neuropathol; 2018 Aug; 136(2):273-291. PubMed ID: 29564591
    [TBL] [Abstract][Full Text] [Related]  

  • 29. IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection.
    Beiko J; Suki D; Hess KR; Fox BD; Cheung V; Cabral M; Shonka N; Gilbert MR; Sawaya R; Prabhu SS; Weinberg J; Lang FF; Aldape KD; Sulman EP; Rao G; McCutcheon IE; Cahill DP
    Neuro Oncol; 2014 Jan; 16(1):81-91. PubMed ID: 24305719
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic and radiographic correlates of a prospectively collected molecularly profiled cohort of IDH1/2-wildtype astrocytomas.
    Lin AL; Rosenblum M; Mellinghoff IK; Tabar VS; Ogilvie S; Schaff L; Yang TJ; Young RJ; Taylor BS; Jonsson P; Bale TA
    Brain Pathol; 2020 May; 30(3):653-660. PubMed ID: 31984581
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A novel all-in-one intraoperative genotyping system for IDH1-mutant glioma.
    Ohka F; Yamamichi A; Kurimoto M; Motomura K; Tanahashi K; Suzuki H; Aoki K; Deguchi S; Chalise L; Hirano M; Kato A; Nishimura Y; Hara M; Kato Y; Wakabayashi T; Natsume A
    Brain Tumor Pathol; 2017 Apr; 34(2):91-97. PubMed ID: 28353033
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PDGFRA amplification is common in pediatric and adult high-grade astrocytomas and identifies a poor prognostic group in IDH1 mutant glioblastoma.
    Phillips JJ; Aranda D; Ellison DW; Judkins AR; Croul SE; Brat DJ; Ligon KL; Horbinski C; Venneti S; Zadeh G; Santi M; Zhou S; Appin CL; Sioletic S; Sullivan LM; Martinez-Lage M; Robinson AE; Yong WH; Cloughesy T; Lai A; Phillips HS; Marshall R; Mueller S; Haas-Kogan DA; Molinaro AM; Perry A
    Brain Pathol; 2013 Sep; 23(5):565-73. PubMed ID: 23438035
    [TBL] [Abstract][Full Text] [Related]  

  • 33. IDH1/2 mutations in WHO grade II astrocytomas associated with localization and seizure as the initial symptom.
    Stockhammer F; Misch M; Helms HJ; Lengler U; Prall F; von Deimling A; Hartmann C
    Seizure; 2012 Apr; 21(3):194-7. PubMed ID: 22217666
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A pyrosequencing-based assay for the rapid detection of IDH1 mutations in clinical samples.
    Setty P; Hammes J; Rothämel T; Vladimirova V; Kramm CM; Pietsch T; Waha A
    J Mol Diagn; 2010 Nov; 12(6):750-6. PubMed ID: 20847279
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification of retinol binding protein 1 promoter hypermethylation in isocitrate dehydrogenase 1 and 2 mutant gliomas.
    Chou AP; Chowdhury R; Li S; Chen W; Kim AJ; Piccioni DE; Selfridge JM; Mody RR; Chang S; Lalezari S; Lin J; Sanchez DE; Wilson RW; Garrett MC; Harry B; Mottahedeh J; Nghiemphu PL; Kornblum HI; Mischel PS; Prins RM; Yong WH; Cloughesy T; Nelson SF; Liau LM; Lai A
    J Natl Cancer Inst; 2012 Oct; 104(19):1458-69. PubMed ID: 22945948
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A novel COLD-PCR/FMCA assay enhances the detection of low-abundance IDH1 mutations in gliomas.
    Pang B; Durso MB; Hamilton RL; Nikiforova MN
    Diagn Mol Pathol; 2013 Mar; 22(1):28-34. PubMed ID: 23370430
    [TBL] [Abstract][Full Text] [Related]  

  • 37. IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas.
    Watanabe T; Nobusawa S; Kleihues P; Ohgaki H
    Am J Pathol; 2009 Apr; 174(4):1149-53. PubMed ID: 19246647
    [TBL] [Abstract][Full Text] [Related]  

  • 38. DMBT1 homozygous deletion in diffuse astrocytomas is associated with unfavorable clinical outcome.
    Motomura K; Mittelbronn M; Paulus W; Brokinkel B; Keyvani K; Sure U; Wrede K; Nakazato Y; Tanaka Y; Pierscianek D; Kim YH; Mariani L; Vital A; Ohgaki H
    J Neuropathol Exp Neurol; 2012 Aug; 71(8):702-7. PubMed ID: 22805772
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Non-IDH1-R132H IDH1/2 mutations are associated with increased DNA methylation and improved survival in astrocytomas, compared to IDH1-R132H mutations.
    Tesileanu CMS; Vallentgoed WR; Sanson M; Taal W; Clement PM; Wick W; Brandes AA; Baurain JF; Chinot OL; Wheeler H; Gill S; Griffin M; Rogers L; Rudà R; Weller M; McBain C; Reijneveld J; Enting RH; Caparrotti F; Lesimple T; Clenton S; Gijtenbeek A; Lim E; de Vos F; Mulholland PJ; Taphoorn MJB; de Heer I; Hoogstrate Y; de Wit M; Boggiani L; Venneker S; Oosting J; Bovée JVMG; Erridge S; Vogelbaum MA; Nowak AK; Mason WP; Kros JM; Wesseling P; Aldape K; Jenkins RB; Dubbink HJ; Baumert B; Golfinopoulos V; Gorlia T; van den Bent M; French PJ
    Acta Neuropathol; 2021 Jun; 141(6):945-957. PubMed ID: 33740099
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Isocitrate Dehydrogenase Mutations are Better Prognostic Marker than O6-methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastomas - a Retrospective, Single-centre Molecular Genetics Study of Gliomas.
    Houdova Megova M; Drábek J; Dwight Z; Trojanec R; Koudeláková V; Vrbková J; Kalita O; Mlcochova S; Rabcanova M; Hajdúch M
    Klin Onkol; 2017; 30(5):361-371. PubMed ID: 29031038
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.